Understanding Dormant Cancer Cells: How Chemotherapy Can Trigger Awakening and How Senolytic Drugs Might Prevent Relapse

Breast cancer relapse frequently occurs in distant organs despite successful initial treatment that reduces primary tumors. Underlying this challenge are dormant disseminated tumor cells (DTCs), which remain in the body without causing immediate symptoms but can later activate to cause metastatic disease. These dormant cells are often resistant to systemic chemotherapy, making them a hidden threat in cancer management.

Research has long hypothesized that the reactivation or awakening of dormant DTCs in distant organs leads to metastatic relapse after an asymptomatic period. Yet, direct evidence of this process was lacking, along with a clear understanding of how chemotherapy influences dormant DTCs already in a state of dormancy.

In a recent groundbreaking study published in Cancer Cell, scientists from the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences introduced a novel recombinase-based lineage tracing system called DormTracer. This innovative tool allowed researchers to observe for the first time the awakening of dormant DTCs following persistence in dormancy and to investigate the impact of chemotherapeutic drugs on this process.

The DormTracer system incorporates a doxycycline-induced expression of a modified p27K- fused with Cre recombinase, along with a genetic construct that permanently turns on mCherry fluorescence after activation. Under this system, dormant cells are marked and traced over time, revealing that chemotherapy can indeed prompt dormant DTCs to re-enter active growth.

The study uncovered that this awakening involves complex mechanisms, including fibroblast senescence and the formation of neutrophil extracellular traps (NETs), which create an environment conducive to tumor cell reactivation. Essentially, chemotherapy, while targeting primary tumors, unintentionally facilitates the transition of dormant DTCs to active metastatic cells.

To counteract this unintended consequence, researchers tested a combination therapy that included chemotherapeutic agents alongside senolytic drugs Dasatinib and Quercetin (DQ). These senolytics specifically target and eliminate senescent fibroblasts, thereby disrupting the environment that supports DTC awakening. Results showed that administering DQ alongside chemotherapy significantly reduced lung relapse and improved overall therapeutic control.

This discovery highlights the potential of integrating senolytic drugs into cancer treatment protocols to prevent relapse caused by dormant cell reactivation. The use of DormTracer not only sheds light on the dormancy-to-reactivation transition but also opens new pathways for developing strategies to suppress metastatic recurrence.

Ultimately, this research provides crucial insight into the biological processes underpinning cancer relapse, offering hope for more effective therapies. Clinical trials involving senolytics are already underway, promising a future where relapse due to dormant cell activation can be effectively managed or even prevented.